Aclaris Therapeutics Stock Performance
| ACRS Stock | USD 4.07 0.25 6.54% |
Aclaris Therapeutics holds a performance score of 18 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.48, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Aclaris Therapeutics are expected to decrease at a much lower rate. During the bear market, Aclaris Therapeutics is likely to outperform the market. Use Aclaris Therapeutics downside variance, and the relationship between the sortino ratio and accumulation distribution , to analyze future returns on Aclaris Therapeutics.
Risk-Adjusted Performance
18 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Aclaris Therapeutics are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Aclaris Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 6.54 | Five Day Return (0.97) | Year To Date Return 287.62 | Ten Year Return (63.00) | All Time Return (63.00) |
1 | Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITKJAK3 Inhibitor for the Treatment ... | 09/17/2024 |
2 | Disposition of 9467 shares by Walker Neal of Aclaris Therapeutics subject to Rule 16b-3 | 10/01/2024 |
3 | Citadel Advisors LLC Adjusts Position in Aclaris Therapeutics Inc | 11/15/2024 |
4 | Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline | 11/18/2024 |
5 | Aclaris stock boosted by BTIG on transformative AD drug acquisition and outlook | 11/19/2024 |
6 | Aclaris Therapeutics director acquires 1.5 million in stock | 11/20/2024 |
7 | Acquisition by Leonard Braden Michael of 206025 shares of Aclaris Therapeutics at 1.2443 subject to Rule 16b-3 | 11/21/2024 |
8 | Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference | 11/26/2024 |
| Begin Period Cash Flow | 45.3 M |
Aclaris |
Aclaris Therapeutics Relative Risk vs. Return Landscape
If you would invest 115.00 in Aclaris Therapeutics on September 2, 2024 and sell it today you would earn a total of 292.00 from holding Aclaris Therapeutics or generate 253.91% return on investment over 90 days. Aclaris Therapeutics is currently generating 2.4417% in daily expected returns and assumes 10.5096% risk (volatility on return distribution) over the 90 days horizon. In different words, 93% of stocks are less volatile than Aclaris, and 52% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aclaris Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aclaris Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aclaris Therapeutics, and traders can use it to determine the average amount a Aclaris Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2323
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ACRS | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.51 actual daily | 93 93% of assets are less volatile |
Expected Return
| 2.44 actual daily | 48 52% of assets have higher returns |
Risk-Adjusted Return
| 0.23 actual daily | 18 82% of assets perform better |
Based on monthly moving average Aclaris Therapeutics is performing at about 18% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aclaris Therapeutics by adding it to a well-diversified portfolio.
Aclaris Therapeutics Fundamentals Growth
Aclaris Stock prices reflect investors' perceptions of the future prospects and financial health of Aclaris Therapeutics, and Aclaris Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aclaris Stock performance.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (1.37) % | ||||
| Operating Margin | (2.23) % | ||||
| Current Valuation | 172.04 M | ||||
| Shares Outstanding | 71.43 M | ||||
| Price To Earning | (12.14) X | ||||
| Price To Book | 2.23 X | ||||
| Price To Sales | 10.74 X | ||||
| Revenue | 31.25 M | ||||
| Gross Profit | (60.02 M) | ||||
| EBITDA | (117.56 M) | ||||
| Net Income | (88.48 M) | ||||
| Cash And Equivalents | 248.6 M | ||||
| Cash Per Share | 3.73 X | ||||
| Total Debt | 426 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.99 X | ||||
| Book Value Per Share | 1.82 X | ||||
| Cash Flow From Operations | (78.33 M) | ||||
| Earnings Per Share | (0.52) X | ||||
| Market Capitalization | 290.72 M | ||||
| Total Asset | 197.41 M | ||||
| Retained Earnings | (770.8 M) | ||||
| Working Capital | 97.9 M | ||||
| Current Asset | 86.52 M | ||||
| Current Liabilities | 1.55 M | ||||
About Aclaris Therapeutics Performance
Assessing Aclaris Therapeutics' fundamental ratios provides investors with valuable insights into Aclaris Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Aclaris Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (336.25) | (353.06) | |
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.58) | (0.61) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (0.56) | (0.59) |
Things to note about Aclaris Therapeutics performance evaluation
Checking the ongoing alerts about Aclaris Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aclaris Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aclaris Therapeutics is way too risky over 90 days horizon | |
| Aclaris Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 31.25 M. Net Loss for the year was (88.48 M) with loss before overhead, payroll, taxes, and interest of (60.02 M). | |
| Aclaris Therapeutics currently holds about 248.6 M in cash with (78.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.73. | |
| Aclaris Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference |
- Analyzing Aclaris Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aclaris Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Aclaris Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aclaris Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aclaris Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aclaris Therapeutics' stock. These opinions can provide insight into Aclaris Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.